Biosimilars stocks
바이오시밀러
What are Biosimilars stocks in Korea?
The Biosimilars theme on jonbur groups 13 Korean stocks listed on KOSPI and KOSDAQ, worth ₩138T in total. On Oct 29, 2026 the group moved down 0.64% (weighted by market value); the largest members are Samsung Biologics, Celltrion, Alteogen.
Key facts
- Stocks
- 13
- Total market value
- ₩138T
- Day's move
- −0.64%
- As of
- Oct 29, 2026
- Largest members
- Samsung Biologics, Celltrion, Alteogen
Earnings tracker · 3Q 2025
Past quarter
Combined, for the companies that have reported, vs the same quarter a year ago
| Company | Reported | Revenue | vs a year ago | Operating profit | vs a year ago | vs last quarter | Op. margin |
|---|---|---|---|---|---|---|---|
| Samsung Biologics | Nov 14 | ₩1.7T | +39.9% | ₩729B | +115.3% | +53.2% | 43.9%28.5% |
| Celltrion | Nov 14 | ₩1T | +16.7% | ₩301B | +45.1% | +24.3% | 29.3%23.5% |
| Alteogen | Nov 14 | ₩49B | +902.3% | ₩27B | Turned to profit | Turned to profit | 54.4%−166.8% |
| SAM Chun Dang Pharm | Nov 14 | ₩58B | +10.8% | ₩3.4B | Turned to profit | Turned to profit | 5.9%−1.6% |
| Celltrion Pharm | Nov 14 | ₩138B | +7.8% | ₩16B | +18.0% | +3.8% | 11.7%10.7% |
| Komipharm International | Nov 14 | ₩12B | +13.6% | ₩66M | −92.7% | −96.0% | 0.5%8.2% |
| Prestige BioPharma | Nov 28 | −₩826,582 | Smaller loss | −₩7.1M | Smaller loss | Smaller loss | — |
| ISU Abxis | Nov 14 | ₩16B | +79.5% | ₩562M | +287.3% | −94.0% | 3.6%1.7% |
| Prestige Biologics | Nov 14 | −₩3.2B | Bigger loss | −₩6.2B | Smaller loss | Smaller loss | — |
| CKD Bio | Nov 14 | ₩34B | −22.3% | −₩1.5B | Turned to loss | Turned to loss | −4.3%5.9% |
| Aprogen Biologics | Nov 13 | ₩21B | +45.3% | −₩11B | Smaller loss | Smaller loss | −50.5%−90.4% |
| Samsung Epis Holdings | Not yet | ||||||
| IMBiologics | Not yet | ||||||
Single-quarter figures. Preliminary figures are the company's own early numbers and are replaced by the quarterly report when it's filed. Expected dates are around when each company reported a year ago.
Technical breadth
After the close on Oct 29, 2026- Above 20-day average
- 22.2%
- Above 60-day average
- 22.2%
- RSI above 70
- 0%
- RSI below 30
- 22.2%
- 52-week highs
- 0
- 52-week lows
- 0
Index gauge · Short term
Bearish
0 bullish, 2 neutral, 7 bearish
Index gauge · Medium term
Bearish
0 bullish, 1 neutral, 7 bearish
Technical read
The Biosimilars theme covers 9 Korean stocks, and only 22.2% of them are trading above both their 20-day and 60-day averages. The group has no names at 52-week highs or lows, and its RSI extreme count shows one member near oversold territory at 22.2 with none overbought. The equal-weighted member index sits below its cloud with an RSI of 35.2, and its short- and medium-term signals both read bearish, with 7 of 9 members on the bearish side in each window.
Written by AI from the indicator values above. Not advice.
Share of members, from each member's own indicators; the gauge reads an equal-weighted index of the members. Technical indicators describe past price and volume patterns. They are not predictions or recommendations.
Credit & macro
- MaturitiesOct 23, 202685ISU Abxis: ₩50bn of bonds due in the next 6 months vs ₩23bn cash₩50bn due within 12 months, from the bond filings so far; cash and cash equivalents as of 2026 H1.ISU Abxis
ETFs for this theme
All ETFs →AUM · Flow 1w
Biosimilars
−0.94%바이오시밀러
Biosimilars are copies of biologic drugs, which are complex medicines made from living cells, that are shown to be highly similar to an already-approved reference product in quality, safety, and efficacy. Korean investors group the theme together because several domestic companies, including Samsung Biologics, Celltrion, and Hanmi-linked developers, have built large manufacturing or development capabilities in this area. Because the sector sits at the intersection of pharmaceuticals, contract manufacturing, and patent-expiry timelines, the theme is often discussed as a single category even though individual companies differ in business models.
13 companies · 2 up · 0 flat · 11 down
- Traded value
- ₩213B
- Value vs 20-day average
- 0.64×
- Top gainer
- Prestige Biologics +2.32%
- Largest company
- Samsung Biologics ₩63T
Companies in this theme
| Company | Price | Daily | Traded value | Market cap | NPS |
|---|---|---|---|---|---|
Samsung Biologics207940 · KOSPI | ₩1,366,000 | −0.44% | ₩58B | ₩63T | 6.88% |
Celltrion068270 · KOSPI | ₩189,300 | −0.26% | ₩71B | ₩44T | 7.28% |
Alteogen196170 · KOSDAQ | ₩220,000 | −1.35% | ₩52B | ₩15T | 2.68% |
Samsung Epis Holdings0126Z0 · KOSPI | ₩307,000 | −3.00% | ₩12B | ₩7.6T | 5.70% |
SAM Chun Dang Pharm000250 · KOSDAQ | ₩188,600 | −0.74% | ₩15B | ₩4.4T | 1.34% |
Celltrion Pharm068760 · KOSDAQ | ₩36,800 | −0.81% | ₩1.8B | ₩1.6T | 0.49% |
Komipharm International041960 · KOSDAQ | ₩8,750 | +0.81% | ₩1.8B | ₩653B | 0.02% |
Prestige BioPharma950210 · KOSPI | ₩4,155 | −1.54% | ₩441M | ₩250B | 0.15% |
IMBiologics493280 · KOSDAQ | ₩13,800 | −3.02% | ₩1.3B | ₩205B | — |
ISU Abxis086890 · KOSDAQ | ₩3,490 | −2.92% | ₩163M | ₩142B | 0.20% |
Prestige Biologics334970 · KOSDAQ | ₩1,193 | +2.32% | ₩531M | ₩93B | — |
CKD Bio063160 · KOSPI | ₩12,350 | −0.24% | ₩135M | ₩68B | 0.62% |
Aprogen Biologics003060 · KOSPI | ₩1,380 | −1.00% | ₩124M | ₩42B | 0.08% |
Source: KRX statistical information